Advertisement

Topics

Insmed's lung infection drug gets FDA priority review status

06:04 EDT 17 May 2018 | SmartBrief

The FDA accepted under a priority review status Insmed's Alis, or amikacin liposome inhalation suspension, as a treatment for -More

Original Article: Insmed's lung infection drug gets FDA priority review status

NEXT ARTICLE

More From BioPortfolio on "Insmed's lung infection drug gets FDA priority review status"

Advertisement
Quick Search
Advertisement
Advertisement